Overview A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD） Status: Recruiting Trial end date: 2027-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of TAS-205 in patients with Duchenne muscular dystrophy Phase: Phase 3 Details Lead Sponsor: Taiho Pharmaceutical Co., Ltd.